EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs

Jorge Ibanez-Vega, Robert Teis, Jennifer K Ocasio, Peter Chockley, Aamir Ansari, Alejandro Allo Anido, Sanya Mehta, Michaela Meehl, Brooke Prinzing, Meghan Ward, David Odde, Suzanne Baker und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-013134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Jorge Ibanez-Vega und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Immunological Synapses, Immunotherapy, Adoptive, Glioma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, American Lebanese Syrian Associated Charities, All of Us Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated safety and modest efficacy against diffuse midline gliomas (DMGs), a highly aggressive pediatric brain tumor. However, mechanisms of CAR T-cell resistance in DMG settings remain unknown.

Methods

We compared the efficacy of B7-H3 CAR T-cells between SJ-DIPGX7c (DMG) and U87-MG (adult glioblastoma) patient-derived cell lines and showed impaired efficacy both in vitro and in vivo. We performed live-cell imaging and single-cell RNA sequencing to investigate deficiencies in immune synapse (IS) formation between CAR T-cells and DMGs. Lastly, we genetically deleted RASA2 , a negative regulator of T cell activation, and evaluated the resulting impact on IS formation and quality, as well as in vitro and in vivo functionality.

Results

We show that limited efficacy of B7-H3 CAR T-cells is due to DMG-mediated inefficient interaction between CAR T-cells and DMG cells. Specifically, DMG cells impair the IS formation, resulting in poor CAR T-cell activation, cytokine secretion, and limited anti-tumor response in vivo. RASA2 deletion improved CAR T-cell activation through the formation of a more functional IS. RASA2-deleted CAR T-cells exhibited enhanced calcium flux, increased accumulation of activated signaling molecules and lytic granules at the synapse, and increased actin cytoskeleton dynamics, which produced larger synaptic areas and resulted in enhanced migration ex vivo. Further, RASA2-deleted CAR T-cells demonstrated improved in vitro functionality and superior early in vivo anti-tumor responses against DMGs compared with controls.

Conclusions

Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunological SynapsesImmunotherapy, AdoptiveGliomaReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansMiceCell Line, TumorLymphocyte Activation

Stichwörter der Autor:innen

Central Nervous System CancerChimeric antigen receptor - CARImmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Chemical Engineering and Material Science, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
  • Therapy Modeling and Design Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee, USA Giedre.Krenciute@STJUDE.ORG.

Förderung

  • NINDS NIH HHS
  • American Lebanese Syrian Associated Charities
  • All of Us Research Program
  • American Brain Tumor Association
  • Assisi Foundation of Memphis
  • ChadTough Foundation

Zitieren

APA

Ibanez-Vega, J., Teis, R., Ocasio, J. K., Chockley, P., Ansari, A., Allo Anido, A., Mehta, S., Meehl, M., Prinzing, B., Ward, M., Odde, D., Baker, S., & Krenciute, G. (2026). RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013134

Vancouver

Ibanez-Vega J, Teis R, Ocasio JK, Chockley P, Ansari A, Allo Anido A, et al. RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013134

BibTeX
@article{IbanezVega2026,
  author = {Ibanez-Vega, Jorge and Teis, Robert and Ocasio, Jennifer K and Chockley, Peter and Ansari, Aamir and Allo Anido, Alejandro and Mehta, Sanya and Meehl, Michaela and Prinzing, Brooke and Ward, Meghan and Odde, David and Baker, Suzanne and Krenciute, Giedre},
  title = {RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-013134}
}
Kostenlos starten →